Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 120, Issue 1, Pages 44-52Publisher
WILEY
DOI: 10.1046/j.1365-2141.2003.03948.x
Keywords
myeloma; chromosome 13; cytogenetics; FISH; high-dose therapy
Categories
Funding
- NCI NIH HHS [CA55819] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P01CA055819] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Cytogenetic abnormalities of chromosome 13 (CA 13) and those detected by fluorescence in situ hybridization (FISH 13) have both been associated with poor prognosis in multiple myeloma (MM) patients. The prognostic implications of CA, FISH 13 and other standard laboratory parameters were examined in the first 231 patients enrolled in Total Therapy II, an intensive cytotoxic chemotherapy programme with tandem autotransplants. Three-year projections of event-free survival (EFS) and overall survival (OS) were 71% and 77% respectively. CA 13 was detected in 14% and significantly correlated with FISH 13 (present in 51%), tumour burden, proliferative activity and lactic dehydrogenase (LDH). Both EFS and OS were significantly shorter in patients with CA 13, FISH 13, LDH greater than or equal to 190 U/l, beta2 microglobulin greater than or equal to 4 mg/l and C reactive protein greater than or equal to 4.0 mg/l; other CA was an additional risk factor for OS. Two-thirds of CA 13 patients were identified by FISH 13 and plasma-cell-labelling index (PCLI) greater than or equal to 0.4%; however, PCLI failed to identify additional risk groups in FISH subsets. Although present in considerably fewer patients, CA 13 imparted more rapid relapse (61% at 3 years) and death (43% at 3 years) than FISH 13 (38% and 35%; P = 0.02 and 0.1 respectively) and should be part of the initial work-up of patients with MM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available